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A monolayer hiPSC culture system for autophagy/mitophagy studies in human
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Peter A Barbuti b, Talitha L. Kerriganc,d, Andrew D. Randall c, Maeve A. Caldwell b,e, and Jon D. Lane a
aCell Biology Laboratories, School of Biochemistry, University of Bristol, Bristol, UK; bRegenerative Medicine Laboratory, School of Clinical Sciences,
University of Bristol, Bristol, UK; cInstitute of Biomedical and Clinical Sciences, University of Exeter Medical School, Hatherly Laboratory, Exeter, UK;
dDementia Research Group, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, UK; eTrinity College Institute
for Neuroscience, Trinity College Dublin, Dublin, Ireland
ABSTRACT
Macroautophagy/autophagy cytoplasmic quality control pathways are required during neural develop-
ment and are critical for the maintenance of functional neuronal populations in the adult brain. Robust
evidence now exists that declining neuronal autophagy pathways contribute to human neurodegen-
erative diseases, including Parkinson disease (PD). Reliable and relevant human neuronal model systems
are therefore needed to understand the biology of disease-vulnerable neural populations, to decipher
the underlying causes of neurodegenerative disease, and to develop assays to test therapeutic inter-
ventions in vitro. Human induced pluripotent stem cell (hiPSC) neural model systems can meet this
demand: they provide a renewable source of material for differentiation into regional neuronal sub-
types for functional assays; they can be expanded to provide a platform for screening, and they can
potentially be optimized for transplantation/neurorestorative therapy. So far, however, hiPSC differentia-
tion protocols for the generation of ventral midbrain dopaminergic neurons (mDANs) – the predominant
neuronal sub-type afflicted in PD – have been somewhat restricted by poor efficiency and/or suitability
for functional and/or imaging-based in vitro assays. Here, we describe a reliable, monolayer differentia-
tion protocol for the rapid and reproducible production of high numbers of mDANs from hiPSC in
a format that is amenable for autophagy/mitophagy research. We characterize these cells with respect to
neuronal differentiation and macroautophagy capability and describe qualitative and quantitative assays
for the study of autophagy and mitophagy in these important cells.
Abbreviations: AA: ascorbic acid; ATG: autophagy-related; BDNF: brain derived neurotrophic factor;
CCCP: carbonyl cyanide m-chlorophenylhydrazone; dbcAMP: dibutyryl cAMP; DAN: dopaminergic neu-
ron; DAPI: 4ʹ,6-diamidino-2-phenylindole; DAPT: N-[N-(3,5-difluorophenacetyl)-L-alanyl]-sphenylglycine;
DLG4/PSD95: discs large MAGUK scaffold protein 4; DMEM: Dulbecco’s modified eagle’s medium; EB:
embryoid body; ECAR: extracellular acidification rate; EGF: epidermal growth factor; FACS: fluorescence-
activated cell sorting; FCCP: arbonyl cyanide p-triflouromethoxyphenylhydrazone; FGF: fibroblast growth
factor; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; GDNF: glia cell derived neurotrophic factor;
hiPSC: human induced pluripotent stem cell; LAMP2A: lysosomal associated membrane protein 2A; LT-R:
LysoTracker Red; MAP1LC3: microtubule associated protein 1 light chain 3; mDAN: midbrain dopami-
nergic neuron; MEF: mouse embryonic fibroblast; MT-GR: MitoTracker Green; MT-R: MitoTracker Red;
NAS2: normal SNCA2; NEM: neuroprogenitor expansion media; NR4A2/NURR1: nuclear receptor sub-
family group A member 2; OA: oligomycin and antimycin A; OCR: oxygen consumption rate; PD:
Parkinson disease; SHH: sonic hedgehog signaling molecule; SNCA/α-synuclein: synuclein alpha; TH:
tyrosine hydroxylase; VTN: vitronectin.
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Parkinson disease (PD) is a progressive neurodegenerative
disorder that causes motor, physical and cognitive impair-
ments, leading to a reduction in quality of life and even-
tually, an inability to live independently. PD affects around
1% of the population aged over 65 and around 4% aged
over 85. In the UK, there are currently ~145,500 PD
patients, with the expectation that by 2065 the prevalence
and incidence rates for PD in the UK will have almost
doubled [1]. Classic PD symptoms (e.g., tremors at rest,
postural instability, stiffness, dyskinesia) result from falling
levels of the catecholaminergic neurotransmitter, dopamine,
caused by the degeneration of midbrain dopamine-
producing neurons (mDANs) [2]. Consequently, there is
a need to better understand how PD pathophysiology
affects these neurons. To achieve this goal, relevant and
amenable cell-based assay systems are required for func-
tional tests in vitro.
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In PD, the most susceptible neurons are the neuromelanin-
pigmented mDANs located in the substantia nigra pars com-
pacta (SNpc; A9) [3]. To a lesser extent, dopaminergic neu-
rodegeneration occurs in other brain regions such as the
ventral tegmental area (A10) from where neurons project to
the limbic system to establish the mesolimbic dopaminergic
pathway. At later stages of the disease, neurodegeneration
extends to other brain regions in a pattern that explains the
later stage, non-motor symptoms of PD (e.g., depression,
cognitive impairment, dementia) [4–6]. Although PD is pri-
marily idiopathic, 5-10% cases are familial, with specific
mutations associated with autosomal dominant and autoso-
mal recessive forms [7]. To date, 21 genes with PD-causing
mutations have been recognized, and several factors asso-
ciated with increased risks of developing sporadic PD have
been identified by meta-analysis [8] and genome-wide asso-
ciation studies/GWAS [9].
A prominent feature of PD is the formation of intracellular
inclusions called Lewy Bodies, consisting mainly of filamen-
tous SNCA (alpha-synuclein) protein aggregates that are toxic
to mDANs [10]. Autophagy counters the accumulation of
these toxic inclusions (see [11]), emphasizing the need for
efficient cytoplasmic quality control. Furthermore, being
extensively arborized, mDANs are especially sensitive to
changes in energy homeostasis [12,13]. They employ L-type
CACNA1D voltage-gated Ca2+ channels to provide tonic
dopamine release at the striatum [12] via slow, broad action
potentials [14,15]. This necessitates efficient energy-
dependent [Ca2+] control processes – including transporter-
mediated efflux across the plasma membrane [12,16–18] and
mitochondrial Ca2+ sequestration [13] – and efficient mito-
chondrial quality control mechanisms. Tellingly, mitochon-
drial malfunctions have been strongly associated with PD (e.g.
[19],), highlighting that efficient autophagy/mitophagy regu-
lation is critical for mDAN functional maintenance.
The links between failing autophagy/mitophagy pathways
and PD have been the focus of several studies on the causes of
inherited PD. Autosomal dominant mutations in the retromer
component, VPS35/PARK17, cause late-onset PD [20]. VPS35
facilitates retrograde transport of endosomal proteins to the
trans-Golgi network or plasma membrane, and mutations
have been suggested to interfere with LAMP2A-dependent
chaperone-mediated autophagy (CMA) [21], ATG9A traffick-
ing during macroautophagy [22], and DNM1 L/DRP1-
mediated mitochondrial network dynamics [23]. Mitophagy
can be triggered by PINK1-mediated PRKN recruitment to
depolarized mitochondria via phosphorylation and ubiquity-
lation signaling, and recruitment of autophagy receptors [24–
29]. Interestingly, PINK1 and PRKN are not essential for
housekeeping mitophagy in flies and in mice [30,31], so
further work is needed to understand the precise regulatory
pathways controlling autophagy/mitophagy in mDANs.
Protocols for the generation of human mDANs in vitro for
PD-related research include dopaminergic neural differentia-
tion from embryonic stem cells (ESCs) or human induced
pluripotent stem cells (hiPSCs), and direct conversion of
stem cells or fibroblasts by forced expression of dopaminergic
neuronal factors (see [32]). hiPSC technology provides
a flexible and relatively straightforward approach to study
the underlying causes of neural disturbances in vitro, while
also being amenable for cellular transplantation [33–36].
Differentiated cells (e.g., skin fibroblasts) are re-programmed
toward a stem cell state through the addition of factors first
described by Yamanaka [37]. hiPSC lines can then be differ-
entiated into mDANs through the timely addition of
a cocktail of growth and patterning factors, and cytokines
and inhibitors that mimic in vivo dopaminergic neural devel-
opmental process. To specify midbrain mDANs, these
include: SMAD signaling inhibitors to suppress mesodermal
fate (e.g., LDN193189, NOG [noggin], SB431542); patterning
morphogens (e.g., FGF8, SHH, WNT); mitogens (e.g., EGF,
heparin); and survival/dopaminergic identity factors (e.g.,
BDNF, GDNF) [32]. Non-adherent/embryoid-body (EB) or
adherent monolayer differentiation protocols can be
employed, each having particular advantages and disadvan-
tages. By whichever approach, mDANs need to: (i) co-express
neuronal (e.g., TUBB3/βIII-tubulin/TUJ1), dopaminergic
(e.g., TH [tyrosine hydroxylase]), and midbrain (e.g.,
FOXA2, LMX1A) markers; (ii) be able to survive in vitro,
and elongate axons with evidence of synapses; (iii) be able
to synthesize dopamine; (iv) display evidence of electrical
activity; (v) have the capability to reverse PD-like symptoms
in animal models without side effects if to be used for cell-
based therapies [38].
Despite the obvious potential of hiPSCs for studying
autophagy pathways in human mDANs, relatively few PD-
related studies have been attempted to date using this
approach, and most did not provide a full characterization
of the cells under study (for discussion, see [39]). This argues
for the need for efficient, reliable hiPSC differentiation pro-
tocols to obtain sufficient numbers of confirmed mDANs for
single-cell and population-based autophagy/mitophagy assess-
ments in PD. Here, we describe an improved, monolayer
protocol that can reliably and rapidly generate >70% verified
human mDANs in a format that enables imaging-based
autophagy studies in PD-relevant cells. We present a basic
characterization of the biology of these cells, including tem-
poral transcriptional profiling of several macroautophagy/
mitophagy genes. We suggest that this protocol will be useful
for labs wishing to study the basic mechanisms of autophagy
regulation in human mDANs in vitro, how disease-associated
mutations alter these parameters, and for use as an amenable
drug-screening platform for PD research.
Results and discussion
Comparing differentiation protocols for hiPSC-derived
mDANs
We compared several existing hiPSC differentiation protocols
for human mDANs. Firstly, an EB-based protocol that was
originally configured to generate basal forebrain cholinergic
neurons [40] was adapted to promote mDAN differentiation.
We omitted EGF (favors glial differentiation [41,42]), and
included: purmorphamine (SHH agonist); FGF8/FGF8A;
ascorbic acid (AA; improves mDAN survival [43]); BDNF
(improves neuronal survival through activation of NTRK2
receptors, and enhances dopamine release/uptake [44,45]);
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GDNF (promotes mDAN growth and survival [46]); db-
cAMP (upregulates TH synthesis, and promotes neuronal
differentiation/survival [47–49]); DAPT (NOTCH inhibitor
that promotes neuronal differentiation [50]); and TGFB3
(increases responsiveness to GDNF, and promotes neurite
outgrowth and neuronal survival [51]; Figure S1A). Cell
populations generated labeled strongly for TUBB3, TH, and
FOXA2, indicating the presence of abundant mDANs (Figure
S1B and C). Cell bodies were mostly located within the EB,
with abundant axons extending radially for several mm
(Figure S1B and C), meaning that cell characterization could
only be accurately carried out on cells migrating beyond the
periphery of the EB. Focusing on those cells at
differentiation day 55–60, 92.0 ± 0.9% were TUBB3-positive,
of which 28.3 ± 0.7% were also TH-positive (i.e., 26.3 ± 0.7%
of total cells counted; means ± SEM [Figure S1D]). Moreover,
FOXA2 was expressed in 75.6 ± 1.4% of these cells, and
29.2 ± 0.9% of these were also TH-positive (22.3 ± 0.9% of
total cells; Figure S1E). Longer differentiation times (75–80;
95–100 d) did not increase the numbers of FOXA2-positive
midbrain cells; however, the proportion of measurable TH-
positive cells did increase significantly, with mDAN numbers
peaking at ~55% (Figure S1 F).
Despite the good yield of mDANs generated using this
EB-based protocol (Figure S1), it soon became clear that
autophagy assessments would be very challenging.
Achieving high numbers of mDANs required prolonged
total time in culture (>100 d), which is restrictive and
costly while isolating individual cells for imaging studies
of cell bodies and axons, or flow cytometry analysis, was
not straightforward. Poor antibody and/or viral penetrance
into the EB meant that accurate characterization and func-
tional studies would also be limited (data not shown);
meanwhile, neurons generated using this protocol tended
to cluster together and peel away from the coverslip surface
upon gentle agitation (data not shown). To arrive at a more
reliable mDAN culture method, we therefore compared the
practical ease and effectiveness of other published differen-
tiation methods optimized for neurons in monolayers
(namely, the Jaeger et al. [52] and Kirkby et al. [53] pro-
tocols), against our own mDAN-directed modification of
the neocortical differentiation method described by Nistor
et al. [54,55] – itself a xeno- and feeder-free adaption of the
Shi et al. protocol [54,55].
In pilot neuralizations, the yield of midbrain FOXA2-
positive cells was high using the Jaeger et al. method [52]
(65.6 ± 3%), but the proportion of cells expressing TH did not
exceed 12% of the total cell population (11.7 ± 0.9%; data not
shown). Meanwhile, in our hands, the Kirkeby et al. protocol
[53] generated lower mDAN numbers in a single neuraliza-
tion attempt (data not shown). Clearly, further optimization
would have improved mDAN efficiency using these protocols;
however, based on the outcome of pilot neuralizations (see
below), we focused on adapting the Nistor et al. protocol for
the specification of mDANs for our studies. To do so, we
supplemented N2B27 differentiation media with the neural
fate inducing factors LDN193189 (100 nM) and SB431542
(10 μM), and the regional specification factors, SHH-C24II
(200 ng/ml) and CHIR99021 (a GSK3 inhibitor/WNT
signaling activator; 0.8 μM) (Figure S2A). Using this
approach, we generated healthy, dispersed neuronal cultures,
with relatively high numbers of FOXA2/TH-positive neurons
(~60% TUBB3-positive; ~43% FOXA2-positive; ~11% TH/
FOXA2-positive: Figure S2B and C).
An optimized protocol for the rapid and efficient
generation of human mDANs from hiPSCs
Our final hiPSC differentiation protocol is shown schemati-
cally in Figure 1A, with example fields of NAS2-derived cells
co-labeled for TH and either TUBB3 or FOXA2 shown in
Figure 1B,C. Using this protocol with the NAS2 hiPSC line,
we routinely achieved TH-positive cell yields (TH/total)
exceeding 65% (67.1 ± 1.3% at differentiation day 30–35;
means ± SD; Figure 1D), within a neuronal population of
82.1 ± 1.3% (TUBB3-positive/total cells), of which 81.8 ± 1.3%
neurons were also TH-positive (i.e., TH- and TUBB3-positive;
Figure 1D). Importantly, the midbrain identity of these cells
was very high (81.1 ± 1.1% FOXA2-positive/total cells), with
81.9 ± 1.2% of these co-expressing TH (i.e., TH- and FOXA2-
positive mDANs; Figure 1D). We have successfully repeated
this protocol using other iPSC and ES cell lines, including
AST23 (see Figure 1E), SHEF6, MSU, and PAR3B (data not
shown).
To arrive at this efficient protocol, we first confirmed
that inclusion of FGF8 did not improve the proportion of
midbrain cells (49.5 ± 10% FOXA2-positive cells without
FGF8; 44.8 ± 10.8% with FGF8; Figure S3A and B) [53,56],
whereas increasing GDNF and DAPT concentrations (to
20 ng/ml and 10 μM, respectively) resulted in an almost
2-fold increase in TH-positive DANs (11.1 ± 5.7% at lower
versus 19.8 ± 5.4% at higher concentrations; total TUBB3-
positive neuronal populations were comparable,
62.7 ± 8.0% at lower versus 69.1 ± 11.5% at higher con-
centrations) (Figure S3 C and D). We next postulated that
increasing the concentration of SHH-C24II, while simulta-
neously decreasing the concentration of the WNT agonist,
CHIR99021, would enrich for mDANs. This is because
dorsoventral specification is mediated by gradient competi-
tion between these factors [57]. Four combinations were
tested in parallel neuralizations (NAS2 hiPSC line): (i) no
SHH-C24II, no CHIR99021; (ii) 200 ng/ml SHH-C24II,
0.8 μM CHIR99021 (as used in previous studies [53,56]);
(iii) 300 ng/ml SHH-C24II, 0.8 μM CHIR99021; (iv)
300 ng/ml SHH-C24II, 0.6 μM CHIR99021 (Figure 2A,B).
Although the total neuronal population remained similar in
all four combinations (means ± SD: [i] 68 ± 10.3%; [ii]
69.1 ± 11.5%; [iii] 67 ± 9.5%; [iv] 74.6 ± 9.2%), the DAN
percentage of both the total cell (TH-positive/total cells: [i]
no TH-positive cells; [ii] 19.8 ± 5.4%; [iii] 25.2 ± 5.3%; [iv]
43.3 ± 5.8%) and the neuronal population (TH/TUBB3-
positive cells: [i] no TH-positive cells; [ii] 28.6 ± 5.6%;
[iii] 38.5 ± 11.55%; [iv] 58.7 ± 9.5%) were significantly
higher using 300 ng/ml SHH, 0.6 μM CHIR99021
(Figure 2B). Using this optimal condition, almost all the
TH-positive cells co-expressed FOXA2 (~ 99%), suggesting
that the neurons generated were of midbrain, dopaminergic
specification (i.e., mDANs). Immunoblotting for TH at
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differentiation day 25–30 supported the imaging data, in
that at the optimal SHH-C24II/CHIR99021 concentrations,
TH expression was highest (Figure 2C).
We hypothesized that improving the early production of
midbrain-identity cells in the culture would be an effective
way to increase the final yield of mDANs. To achieve this, we
introduced additional passaging steps at differentiation days 3
and 7 of neural induction and patterning (see Figure 1A),
based on reports demonstrating that expression of the plur-
ipotency marker, POU5F1/OCT4, is almost completely
diminished at day 3 of neural induction/patterning
[52,53,56,58]. To select for established ventral mDAN pro-
genitors, we dissociated (with Accutase) and passaged cells on
poly-ornithine/laminin-coated dishes, as laminin favors neu-
ronal progenitor attachment [59]. As shown in Figure S4, this
yielded neural progenitor populations that were almost
entirely FOXA2- and LMX1A-positive (differentiation day
12) – thereby confirming floor plate mDAN progenitor status.
Characterization of mDAN cultures generated using the
optimized monolayer protocol
To further characterize mDAN cultures generated using the opti-
mized, monolayer protocol, we carried out qRT-PCR of a range of
relevant pluripotency and ventral midbrain marker genes in our
neuronal cultures enriched for mDANs. We compared condi-
tions: (i) no SHH-C24II, no CHIR99021; (ii) 200 ng/ml SHH-
C24II, 0.8 μM CHIR99021; (iv) 300 ng/ml SHH-C24II, 0.6 μM
CHIR99021 (Figure 3 shows data from a single neuralization
representative of 3 repeats with similar outcomes using the
NAS2 hiPSC line). Expression of pluripotency genes POU5F1
and NANOG declined by day 5 in all conditions, and remained
low thereafter, demonstrating that the hiPSCs had undergone
differentiation (Figure 3A,B). FOXA2 expression was significantly
greater at day 5 in the 2 SHH/CHIR combinations tested com-
pared to the no SHH-C24II/CHIR99021 control and remained
elevated thereafter demonstrating induction of midbrain tran-
scripts (Figure 3C). Expression of CORIN (a floorplate marker)
was initiated later (day 20), but once again, only in the SHH-C24II
/CHIR99021 treated cultures where it was significantly increased
compared to the control (Figure 3D). Expression of the midbrain
LIM family transcription factor LMX1A increased significantly
at day 10 only in the 300 ng/ml SHH-C24II/0.6 μM CHIR99021
group (iv) but needed 20 d to significantly increase with the
200 ng/ml SHH-C24II/0.8 μM CHIR99021 combination (ii)
(Figure 3E). Even at this stage, we recorded a significant difference
in LMX1A expression between the two SHH-C24II/CHIR99021
combinations (Figure 3E). Importantly, expression of TH was
Figure 1. The final optimized monolayer hiPSC mDAN differentiation protocol. (A) Schematic of the protocol. Refer to Materials and Methods for concentrations.
Passaging steps are indicated with red lines. Detailed, stepwise methodology can be found in [80]. (B, C) Confocal immunofluorescence imaging of day 35 neuronal
cultures (NAS2 hiPSCs) generated using the final protocol. (B) Cultures labeled with anti-TUBB3 (TUJ1) and anti-TH antibodies and stained with Hoescht. (C) Cultures
labeled with anti-FOXA2 and anti-TH antibodies and stained with Hoescht. (D) Quantitation of cell identity in day 35 neuronal cultures. Data show means ± SD for 3
independent terminal differentiations seeded from a single neuralization. Four fields per coverslip were analyzed. (E) Confocal immunofluorescence imaging of day
35 AST23 cultures. Bars: 50 μm.
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found to increase significantly at both SHH-C24II/CHIR99021
combinations at day 20, but the 300 ng/ml SHH-C24II/0.6 μM
CHIR99021 combination gave the strongest TH induction
(Figure 3F). Together, these data are consistent with the immu-
nological characterization suggesting that combination (iv)
300 ng/ml SHH-C24II/0.6 μM CHIR99021 was best suited for
mDANpatterning and that 20 d of differentiation is theminimum
required to trigger expression of important midbrain, dopaminer-
gic markers.
To temporally define midbrain dopaminergic gene expres-
sion, we carried out a qRT-PCR analysis of our mDAN-
enriched neuronal cultures differentiated for up to 60 d in
the optimal SHH-C24II/CHIR99021 combination; i.e., condi-
tion (iv) 300 ng/ml SHH-C24II/0.6 μM CHIR99021. Changes
in FOXA2 expression appeared biphasic, increasing early
on day 10, then again at day 45 (Figure 4A), whereas expres-
sion of dopaminergic markers TH and DDC (DOPA decar-





(i) 0 ng/ml SHH; 0 µM CHIR (ii) 200 ng/ml SHH; 0.8 µM CHIR
(iii) 300 ng/ml SHH; 0.8 µM CHIR (iv) 300 ng/ml SHH; 0.6 µM CHIR
0 ng/ml SHH; 0 µM CHIR
200 ng/ml SHH; 0.8 µM CHIR
300 ng/ml SHH; 0.6 µM CHIR

















































































Figure 2. Optimizing SHH-C42II and CHIR99021 concentrations during neural induction for improved mDAN differentiation efficiency. Images (A) and quantification
(B) of day 35 mDAN cultures (NAS2 hiPSCs) labeled with anti-TUBB3 (TUJ1) and anti-TH antibodies and counter-stained with Hoescht. 4 separate conditions were
tested: (I) no SHH, no CHIR99021; (ii) 200 ng/ml SHH, 0.8 μM CHIR99021; (iii) 300 ng/ml SHH, 0.8 μM CHIR99021; (iv) 300 ng/ml SHH, 0.6 μM CHIR99021. Data show
means ± SD for 3 independent terminal differentiations seeded from a single neuralization. Four fields per coverslip were analyzed. (C) Immunoblotting for TH
expression in lysates of cells at differentiation day 30, generated using conditions (i), (ii) and (iv). * P < 0.05; ** P < 0.01; *** P < 0.001. Bars: 50 μm.
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TH showed a further sharp upturn between days 45–60 sug-
gesting that prolonged differentiation favors dopaminergic
identity (Figure 4B). Expression of NR4A2/NURR1 –
a nuclear transporter that supports dopaminergic status
[60,61] – and KCNJ6 – a potassium channel needed to sup-
port dopaminergic neuronal function – remained relatively
low until day 60 (Figure 4D,E). Together, these data clarify
the temporal nature of key gene expression in our
monolayer differentiation system: using this protocol, it is
possible to generate abundant FOXA2- and TH-positive
mDANs within 25–30 d for imaging-related studies, but
a longer differentiation period of 45–60 d is advised for
studies in which maximal expression of many key midbrain,
floorplate and/or dopaminergic markers is necessary (e.g., for
physiological experiments). Interestingly, maturing mDAN
cultures contained abundant astrocytes (as determined by
anti-S100B immunostaining; Figure S5A), indicating that
glial support is present in these cultures, and relative glial
numbers increased with differentiation phase duration (from
~10% at day 30 to ~25% at day 50–60; Figure S5B). mDANs at
differentiation day 50 expressed the synaptic marker DLG4
(PSD95) in punctate structures (Figure S6A); meanwhile,
electrophysiological analysis showed that the differentiated
neurons could fire action potentials and have voltage-gated
K+ and Na+ currents at day 70 (15 out of 20 patched cells
shared this profile; Figure S6B-D).
Figure 3. qRT-PCR expression profiling of pluripotency, midbrain, and dopaminergic markers during early differentiation under different SHH-C42II/CHIR99021
combinations in neuronal cultures enriched for mDANs. Differentiation was carried out using the optimized monolayer protocol, using NAS2 hiPSCs, with SHH-C42II
/CHIR99021 ratios as follows: (I) no SHH-C42II, no CHIR99021; (ii) 200 ng/ml SHH-C42II, 0.8 μM CHIR99021; (iv) 300 ng/ml SHH-C42II, 0.6 μM CHIR99021. Results are
from a single neuralization, and values are presented as means ± SEM of 3 terminal differentiations, fold-change versus hiPSCs. (A, B) Data are compared against
hiPSC levels for these pluripotency markers, where: $$$ P < 0.001. (C-F) For these midbrain, floorplate and dopaminergic markers, data are compared within time-
points and within treatments. Statistical comparisons against hiPSCs are not shown for clarity. ** P < 0.01; *** P < 0.001.
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Preliminary assessment of macroautophagy capability in
hiPSC-derived mDAN cultures
To test the suitability of our hiPSC-derived mDANs for
autophagy research, we first used qRT-PCR to assess the
timings of expression of key macroautophagy and mitophagy
genes, from the hiPSC stage to day 60 of differentiation
(Figure 5). Overall, changes in expression were relatively
small, but some interesting patterns emerged. ATG5,
MAP1LC3B, BECN1/Beclin 1, and LAMP1 showed similar
profiles, with an initial drop in expression at around day 20
relative to the hiPSC stage, and expression rising again at day
30 to decline once more by day 60 (Figure 5A,C,D,G; signifi-
cant only for MAP1LC3B and LAMP2). ATG16L1 and the
autophagy receptors SQSTM1 and OPTN showed an initial
decline in expression at day 20, followed by a gradual increase
to day 60 (Figure 5B,F,H). PINK1 followed a similar pattern
(Figure 5I), but BNIP3 L (NIX) differed with expression
changing little during differentiation (Figure 5J). Finally,
AMBRA1 expression showed a steady increase up to day 60
(Figure 5E). Broadly, these data are consistent with an initial
decline in macroautophagy potential during early differentia-
tion (day 10–20), followed by a regaining of macroautophagy
gene expression as mDANs mature. Notably, re-activated
expression of several macroautophagy genes (at day 30) cor-
related with expression of the dopamine synthesis enzymes,
TH and DDC (Figure 4B,C).
To provide proof-of-principle macroautophagy analysis in
hiPSC-derived mDANs, we tested: (i) immunostaining using
anti-WIPI2 (Figure 6A) and anti-MAP1LC3B (data not
shown) antibodies; (ii) CYTO-ID staining (Figure 6B); (iii)









































































































































































Figure 4. qRT-PCR analysis of temporal changes in midbrain/floorplate and A9 dopaminergic maturity markers in neuronal cultures enriched for mDANs. NAS2 hiPSCs
were differentiated according to the optimized monolayer protocol, using 300 ng/ml SHH-C42II, 0.6 μM CHIR99021. (A) Floorplate/midbrain marker FOXA2. (B-D)
Dopaminergic markers, TH, DDC, and NR4A2. (E) The A9 dopaminergic maturity marker, KCNJ6. Results are from a single neuralization, and values are presented as
means ± SEM of 3 terminal differentiations as fold-change from hiPSCs. ** P < 0.01; *** P < 0.001.
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GFP-ATG5 expression (Figure 6D); (v) immunoblotting for
MAP1LC3B lipidation and SQSTM1 turnover (Figure 6E); (vi)
ultrastructural analysis of autolysosomal vacuoles (Figure 7A-C).
Anti-WIPI2 antibodies worked well in methanol-fixed hiPSC-
derived mDANs (Figure 6A), and WIPI2 puncta were found to
significantly increase in TH-positive neurons in 60-d mDAN
cultures treated with 1 μM AZD8055 (MTOR inhibitor; 4 h)
compared with control, indicating enhanced autophagosome
assembly site initiation (Figure 6A). On the other hand, the anti-
MAP1LC3B antibodies that we have so far tested have not been
successful due to difficulties distinguishing true autophagic
puncta from fluorescent cell debris (formaldehyde andmethanol
fixation gave similar results; data not shown). Instead, we recom-
mend the CYTO-ID kit for rapid autophagosome/autolysosomal
staining in hiPSC-derived neurons (Figure 6B). This green fluor-
escent cationic amphiphilic tracer dye gives excellent overlap
with MAP1LC3B-labeled puncta in RPE1 cells in our hands
(data not shown), and enables vital staining of autophagic struc-
tures [62]. Importantly, it can be fixed, thus enabling co-staining
with e.g., anti-TH antibodies (Figure 6B). AZD8055-treated
mDANs were loaded with CYTO-ID, fixed with formaldehyde,
and stained with anti-TH antibodies. This treatment caused
a significant increase in CYTO-ID puncta in TH-positive
mDAN cell bodies in comparison with the DMSO vehicle con-
trols (Figure 6B). Lentiviral GFP-MAP1LC3B and GFP-ATG5
expression each worked effectively for live-cell imaging (Figure
6C,D), but GFP-MAP1LC3B puncta were not well retained
following fixation (data not shown) precluding correlation with
anti-TH staining of fixed cultures.
Immunoblotting demonstrated increased MAP1LC3B lipi-
dation in mDAN cultures treated for 4 h with AZD8055 alone
(not significant) and AZD8055 in the presence of BafA1
Figure 5. qRT-PCR analysis of the temporal expression of autophagy genes as shown during mDAN differentiation in neuronal cultures enriched for mDANs. NAS2
hiPSCs were differentiated according to the optimized monolayer protocol, using 300 ng/ml SHH-C42II, 0.6 μM CHIR. Results are from a single neuralization, and
values are presented as means ± SEM of 3 terminal differentiations as fold-change from hiPSCs. * P < 0.05; ** P < 0.01; *** P < 0.001.
8 P. STATHAKOS ET AL.
(significantly increased) (Figure 6E). Evidence for SQSTM1
turnover in AZD8055-treated mDAN cultures (not signifi-
cant) and stabilization in the presence of BafA1 (significantly
different) was also obtained in treated mDAN cultures
(Figure 6E). Using EM, we observed evidence of autophago-
somes in the neurites of untreated mDAN cultures, with
presumed pre-synaptic vesicle clusters apparent at growth
cone-neurite intersections (Figure 7A). We could also demon-
strate robust increases in autolysosomal vacuole abundance in
neuronal cell bodies treated with BafA1 in the absence or
presence of AZD8055 (Figure 7B,C). Interestingly, and
consistent with the lack of a significant change in
MAP1LC3B lipidation in AZD8055-treated cultures (Figure
6E), there was no apparent quantitative change in autolyso-
somal cytoplasmic volume occupancy in the cell bodies of
neurons treated with AZD8055 alone (Figure 7B,C).
Together, these observations suggest basal and stimulated
efficient autophagic flux in mDANs. Finally, to better under-
stand the behavior of neurons in our mDAN cultures, we
measured axonal growth dynamics in the absence or presence
of BafA1 (to block autophagic flux). Autophagy is known
to influence growth cone stability via the turnover of
Figure 6. Examples of autophagy assessments in hiPSC-derived mDANs. In all cases, mDANs were differentiated from NAS2 hiPSCs using the optimized monolayer
protocol. (A, B) Confocal imaging of day 60 neurons treated for 4 h with AZD8055, then stained for TH alongside (A) WIPI2 and (B) Cyto-ID. Example images to the
left; quantitation to the right. (C) Day 47 neurons transduced with GFP-MAP1LC3B lentivirus and imaged up by time-lapse wide-field microscopy following the
addition of AZD8055 (AZD; 4 h). Dynamic, GFP-MAP1LC3B-positive autophagic puncta can be observed within soma and neurites (arrows). (D) Day 25 neurons were
transduced with lentivirus expressing GFP-ATG5, and imaged by time-lapse wide-field microscopy following the addition of AZD8055 (AZD; 4 h). GFP-ATG5 puncta
(arrows) can be observed appearing, becoming brighter, then fading within the soma. (E) Representative immunoblots (left) for the indicated proteins from mDANs
(differentiated at day 28–40) after 4 h treatment with AZD (1 μM) and/or BafA1 (20 nM), and densitometry quantitation (right). Arrow indicates LC3-II. Data are mean
± SEM (n = 2). Statistical analysis was performed using one-way ANOVA followed by a Tukey’s multiple comparisons test; P < 0.05; ** P < 0.01. Bars: 10 μm.
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microtubule regulators [63]. In our cultures, axonal basal
growth rates were measured to be ~0.8 μm/min, increasing
marginally to ~1.0 μm/min in the presence of BafA1
(Figure 7D,E).
Assessing mitochondrial properties and mitophagy
quality control in mDANs
We used several tools for proof-of-principle analysis of mito-
chondrial properties in hiPSC-derived mDANs. Firstly, we
monitored CCCP-induced mitochondrial membrane potential
collapse by live-cell imaging (Figure 8A), and flow cytometry
(Figure 8B). For live imaging, we loaded 60-d mDAN cultures
with MT-R (membrane potential-dependent CMXRos) and
MT-GR (membrane potential-independent) dyes [64], and
measured fluorescence intensities in regions of interest con-
taining individual cell bodies as a function of initial fluores-
cence intensity. Cells were confirmed to be mDANs by fixing
and labeling with anti-TH antibodies at the end of the experi-
ment (not shown). Figure 8A shows the decline in fluores-
cence (MT-R/MT-GR intensity) plotted as % reduction,
confirming that 10 μM CCCP caused mitochondrial mem-
brane potential collapse in human hiPSC-derived mDANs.
We next tested whether flow cytometry could be used as
Figure 7. mDAN ultrastructure and growth cone dynamics. (A) Example EM images of untreated mDAN cultures: (I) shows a cell body (soma) region and neurite; (ii)
shows a growth cone adjacent to neurites, with evidence of docked vesicular clusters; (iii) shows autophagosomal structures in a neurite. S = soma; N = neurite;
GC = growth cone; AV = autophagic vacuole; V = vesicular cluster. (B) Example images and (C) quantitation (% cytoplasmic area occupancy) of autolysosomal profiles
in the cell bodies of neurons present in mDAN cultures treated for 4 h with AZD8055 in the absence or presence of BafA1 (n = 12 cell bodies per condition). (D)
Example frames from a live-cell imaging time-lapse sequence and (E) quantitation of axonal growth code extension rates in control or BafA1-treated mDAN cultures.
Bar: 10 μm.
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a rapid, objective tool to monitor mitochondrial membrane
potential in mDAN cultures. Here, population-level measure-
ments are necessary, emphasizing the need for cultures with
high numbers of verified mDANs. To ensure that we mea-
sured only neurons, we transduced cultures with lentiviruses
expressing GFP from the SYN1 promoter. Thus, we could be
confident that ~70-80% of cells analyzed would be TH-
positive mDANs (Figure 1D). We treated cultures for 3 h
with 10 μM CCCP or vehicle control (DMSO), labeled with
MT-R, then dissociated into individual cells using Accutase
before being analyzed on a BD Influx cell sorter. Events were
sequentially gated on forward/side scatter, Draq7 fluorescence
(for viable cells), and GFP (to assess neurons only)/MT-R
fluorescence (not shown). MT-R fluorescence was then quan-
titated, revealing that CCCP addition caused a significant
drop in mitochondrial membrane potential in neurons, as
expected (Figure 8B). On preparing neuronal cultures for
flow cytometry, damage to neurites will inevitably occur,
which may have an impact on overall cell viability/stress. It
is, therefore, important to consider any data obtained using
such an approach alongside orthogonal techniques.
Simultaneous measurements of oxygen consumption
(OCR) and extracellular acidification (ECAR) rates provide
valuable information about mitochondrial oxidative phos-
phorylation (OXPHOS) and aerobic glycolysis rates, respec-
tively. We used a Seahorse XFp device to obtain baseline
measurements of OXPHOS and glycolysis in 70-d mDAN
cultures grown in the presence of either glucose or galactose
(for 1 or 3 d) to force usage of mitochondrial OXPHOS
(Figure 8C,D). FCCP concentration was optimized at 1 μM.
Following 1-d growth in galactose, maximum OCR measure-
ments were not significantly different from the glucose-
treated samples, but ECAR was significantly reduced
(Figure 8C). By contrast, after 3-d growth in galactose
media, mDAN cultures had significantly higher maximum
OCR levels (Figure 8D), suggesting that this incubation length
was sufficient to trigger a switch toward OCR dependency.
This analysis demonstrates the value of Seahorse measure-
ments of hiPSC-derived mDAN cultures; further work will
be needed to determine the relative influence of neurons and
astrocytes in these metabolic shifts.
Analysis of baseline mitochondrial morphometric para-
meters in fixed, untreated TH-positive mDANs, showed that
mitochondrial length ranged from 0.8 to 3.2 μm
(average = 2.13 ± 0.6 μm), with mean linear axonal distance
between mitochondria being 4.1 ± 2.2 μm (mean ± SD for 60
TH-positive axons; 245 mitochondria) (example images in
Figure 9A,B). To measure mitochondrial dynamics by live-
cell imaging, MT-R stained mDAN cultures were imaged for
up to 16 h, and were subsequently fixed and stained with anti-
TH antibodies for retrospective confirmation of mDAN iden-
tity. Transport rates for motile mitochondria were measured
to be 0.6 ± 0.2 μm/s (50 motile mitochondria measured across
3 imaging dishes) (data not shown). To provide proof-of-
principle analysis of mitophagy in living human mDAN cul-
tures, we measured co-localization of MT-GR and
LysoTracker red (LT-R) in neuronal cell bodies in mDAN
































































































































Figure 8. Characterization of mitochondrial properties in day 60 mDAN cultures differentiated from NAS2 hiPSCs using the optimized monolayer culture. (A) Imaging
mitochondrial membrane potential collapse. Neurons were loaded with MT-R and MT-GR then imaged by wide-field fluorescence microscopy in the absence or
presence of 10 μM CCCP. Data show means ± SD of 25 individual neurons from a single neuralization, verified by post-fix anti-TH labeling (not shown). (B)
Measurements of mitochondrial membrane potential collapse in neuronal cultures by flow cytometry. mDAN cultures were transduced with lentiviruses expressing
GFP from the SYN1 promoter, and individual GFP-expressing neurons loaded with MT-R were measured for mitochondrial membrane potential by flow cytometry.
MT-R fluorescence was compared in control (DMSO) and CCCP-treated cells. (C, D) Seahorse Bioanalyzer measurements of OCR and ECAR in mDAN cultures grown for
1 d (C) and 3 d (D) in either glucose or galactose media. ** P < 0.01; *** P < 0.001.
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synthase [complex V] inhibitor) with antimycin A (complex
III inhibitor) (OA), in the absence or presence of leupeptin
(lysosomal protease inhibitor). The data showed that mito-
phagy events increased significantly in the presence of these
inhibitors, with evidence of flux revealed in the OA + leupep-
tin data set (Figure 9C).
Conclusions and future perspectives
The use of iPSCs to generate neurons for autophagy-related
studies of neurodegenerative diseases including PD is wide-
spread and has been reviewed extensively [39,65–67]. It is
clear that there are substantial differences in mDAN differen-
tiation protocols being applied, and varying standards for
assessing mDAN identity/contribution in culture, highlighting
a need for greater consistency. mDANs can be induced from
iPSCs by overexpression of LMX1A. Using such an approach,
neurite morphology defects were reported in LRRK2G2019 S
(leucine-rich repeat kinase 2) mutant cells, corresponding
with evidence of failed autophagic flux [59]. Proportions of
mDANs were relatively low in this study, however (9-29%),
and direct correlation with mDAN reporters was not shown for
all assays [59]. The LMX1A overexpression protocol was also
used to study chaperone-mediated autophagy (CMA) defects in
dopaminergic neurons harboring the LRRK2G2019 S mutation
[68]. Using an embryoid body/neurosphere protocol [69,70],
Fernandes et al. generated mDANs carrying the GBAN370 S
mutation (a PD risk factor), obtaining ~30% TH-positive
/TUBB3-positive neurons [71]. They applied anti-TH staining
in immunoelectron microscopy to reveal altered lysosomes
morphology consistent with impaired autophagic flux in dopa-
minergic neurons [71]. The same differentiation protocol has
been used to study mitophagy in mDANs with mutations in
PRKN or PINK1 [72,73], although in one study, low numbers
of TH-positive cells were reported (11-16%) and midbrain
identity was not confirmed [72]. By including FACS-sorting
with CXCR4/CD184high/CD44− markers to enrich for iPSC-
derived mDANs, the TH+ neuronal population has been raised
to ~50%, and in this study, the mt-mKeima reporter was used
to measure mitophagy in PRKN mutant cells, although correla-
tion with mDAN markers was not shown [74]. In neurosphere
iPSC-derived mDANs, the PARK7/DJ-1G192 C mutation was
shown to influence GBA activity and lysosomal function [75].
TH-positive cells ranged from ~30% (day 30) to ~60% (day 90)
of the total cell population in this study [75]. Using an WNT1-
FGF8-retinoic acid patterning protocol, Hsieh et al. studied
mitochondrial dynamics and mitophagy in iPSC-derived DA
neurons with the LRRK2G2019 S mutation [76]. Mitochondrial
stress parameters and attenuated OPTN and GFP-LC3 recruit-
ment to damaged mitochondria were reported, and mt-
mKeima used to demonstrate delayed mitophagy; however,
mDANs contributed only 10-12% of cells in the population,
meaning that only a small proportion of cells analyzed were
likely to be true mDANs [76].
Figure 9. Examination of mitochondrial properties and quality control in mDANs differentiated from NAS2 hiPSCs. (A, B) Examples of neurons labeled with anti-TH
and anti-ATPB (mitochondrial marker) antibodies. Cell bodies (A) and neurites (B) are shown. (C) Mitophagy analysis by colocalization of MT-G and LT-R in live mDAN
cultures. To the left, example images of control and OA + Leupeptin treated neuronal fields are shown. To the right, data points show individual cells from 3 separate
experiments. ** P < 0.01; *** P < 0.001. Bars: 10 μm.
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The monolayer-based neural differentiation protocol that
we have presented here reliably and reproducibly generates
~70-80% mDANs, in a dispersed culture that is amenable to
diverse imaging and functional assessments of autophagy/
mitophagy-related parameters. The high proportion of con-
firmed mDANs achievable when using this protocol means
that population-based assays are possible, since the contribu-
tion of mDANs to any changes in parameter will be substan-
tial. The presence of astrocytes within maturing cultures likely
provides support for mDANs within the culture, but this
should nevertheless be considered particularly when carrying
out population-based assessments and/or when stressing cul-
tures to analyze mDAN responses since astrocytes can
amplify/elicit neuronal cell stress themselves. Furthermore,
the dispersed nature of the mDANs generated using this
protocol means that fixed and live-cell imaging of autophagy
processes can be carried out as long as care is taken during
fixation and image interpretation. As a xeno- and feeder-free
system, this methodology has the potential to be adapted for
transplantation studies. We suggest that judicious application
of this monolayer protocol for dedicated PD research and/or
as part of functional validation in an important disease-




Seahorse XF base medium (Agilent Technologies,
103193–100); Seahorse XFp FluxPax (Agilent Technologies,
103022–100); Accutase (Thermo Fisher Scientific, A11105-
01); ascorbic acid (Sigma, A5960); AZD8055 (Stratech
Scientific, S1555); B27 (Thermo Fisher Scientific,
17504–044); bafilomycin A1 (BafA1; Enzo Scientific, CM110-
0100); human recombinant BDNF (Preprotech, 450–02); car-
bonyl cyanide m-chlorophenylhydrazone (CCCP; Sigma,
C2759; used at 10 μm); oligomycin (Sigma, O4876; used at
10 μM); antimycin A (Sigma, A8674; used at 1 μM);
CHIR99021 (Axon Medchem, 1386); CytoID (Enzo, ENZ-
51031); 1,4-diazabicylo[2.2.2]octane (DABCO; Sigma,
D27802); 4ʹ,6-diamidino-2-phenylindole (DAPI; Sigma,
D9542); DAPT (Tocris, 2634); db-cAMP (Sigma, D6546);
DMEM-high glucose (Sigma, D5796); DMEM-F12 w/o glu-
cose (Biowest, L0091); DMEM/F-12 + Glutamax (Thermo
Fisher Scientific, 31331–028); KnockOutTM DMEM (KO-
DMEM) (Thermo Fisher Scientific, 10829018); KnockOutTM
serum replacement (KO-SR; Thermo Fisher Scientific,
10828028); Essential 8 medium/E8 supplement (Thermo
Fisher Scientific, A1517001); F12 + Glutamax (Thermo
Fisher Scientific, 31765); FGF2 (PeproTech, 100-18B); FGF8/
FGF8A (R&D Systems, 4745-F8); FN1 (Sigma, F0162); galac-
tose (Sigma, G0750); human recombinant GDNF (Peprotech,
450–10); Glutamax (Thermo Fisher Scientific, 35050–038);
Hoechst 33342 (Thermo Fisher Scientific, 62249); human
INS (Sigma; I9278); laminin (Sigma; L2020); LDN193189
(Sigma; SML0559); LysoTracker Red (LT-R; Thermo Fisher
Scientific, L7528); mitomycin C (Tocris, 5238); MitoTracker
Green (MT-GR; Thermo Fisher Scientific, M7514);
MitoTracker Red (MT-R; CMXROS; Thermo Fisher
Scientific, M7512); monothioglycerol (Sigma, 35,050); N2
(Thermo Fisher Scientific, 17502–048); neurobasal (Thermo
Fisher Scientific, 21103–049); non-essential amino acids
(NEAA; Thermo Fisher Scientific, 11140–035); PD0325901
(Axon, 1408); penicillin/streptomycin (Sigma, P4333); poly-
L-ornithine (PO; Sigma, P4957); polyhema (Sigma, P3932);
purmorphamine (Calbiochem, 540220); RevitaCell (Thermo
Fisher Scientific, A2644501); SB431542 (Tocris, 1614); human
recombinant SHH (sonic hedgehog; SHH-C24II; R &
D Systems, 1845SH025); SYBR Green (Thermo Fisher
Scientific, 4310179); TGFB3 (Peprotech, 100-36E); TF/trans-
ferrin (Sigma, T8158); VTN/vitronectin (Thermo Fisher
Scientific, A14700); Y27632 (Tocris, 1254).
Antibodies used were: rabbit anti-TH (Millipore, AB152);
mouse anti-TH (Santa Cruz Biotechnology, sc-25269); anti-
TUBB3 (TUJ1) (Bio-legend, 801201); anti-FOXA2 (Santa
Cruz Biotechnology, sc-101060); anti-LMX1A (Millipore,
AB10533); anti-LMX1B (Proteintech, 18278); anti-TBR1
(Abcam, AB31940); anti-WIPI2 (BioRad, MCA5780 GA);
anti-MAP1LC3B (Sigma, L7543); anti-SQSTM1 (Abnova,
H00008878); anti-ATP5F1B (Abcam, AB14730); anti-DLG4
(Neuromab, 75028); anti-S100B (Abcam, AB868); anti-SYP
(Abcam, AB32127); anti-SLC17A7 (Synaptic Systems,
135303); Alexa Fluor 488 anti-rabbit (Thermo Fisher
Scientific, A21206); Alexa Fluor 568 anti-rabbit (Thermo
Fisher Scientific, A10042); Alexa Fluor 488 anti-mouse
(Thermo Fisher Scientific, A21202); Alexa Fluor 568 anti-
mouse (Thermo Fisher Scientific, A10037); Alexa Fluor 647
anti-rabbit (Thermo Fisher Scientific, A31573); Alexa Fluor
647 anti-mouse (Thermo Fisher Scientific, A31571); anti-
rabbit HRP (Jackson Immunoresearch, 111035144); anti-
mouse HRP (Jackson Immunoresearch, 115035003).
Cell-lines and culture conditions
All of the functional data presented in this study was obtained
using the “Normal SNCA” (NAS2) hiPSC line [77] (a gift
from Dr. Tilo Kunath, Center for Regenerative Medicine,
University of Edinburgh; used at passages 40–70). We used
several additional stem cell-lines during this development of
our system, including AST23 SNCA triplication 23 hiPSC line
originating from a member of the same family from which the
NAS2 was derived (from Dr. Tilo Kunath [77]); Sheffield 6
(SHEF6) ES line [78] (acquired from the UK-Stem Cell Bank;
used between passage 45–53); Michigan State University
Human 001 (MSU-H001) hiPSC line [79] (a gift from Prof.
Jose Bernardo Cibelli, Cellular Reprogramming Laboratory,
Michigan State University; used between passages: 51–70);
Mouse embryo fibroblasts (MEFs) were derived from preg-
nant mice sacrificed at gestation day 12–13 (E12-E13). These
were inactivated by a 2 h incubation (37°C/5% CO2) in
mitomycin c diluted in MEF media to a final concentration
of 10 μg/ml.
For feeder-dependent human stem cell culture, stem cells
were maintained on MEF feeder layers in stem cell media
consisting of KO-DMEM supplemented with 20% KO-SR, 1%
Glutamax, 1% Pen/Strep, 0.2% β-mercaptoethanol (Sigma,
M6250), 1% NEAA and 20 ng/ml FGF2. Cells were allowed
AUTOPHAGY 13
to form colonies and expand to up to 80% confluency (for
approximately 8 to 10 d). Media was changed daily. Colonies
were pruned every 4 d from differentiated cells and from the
surrounding MEFs. For feeder-free culture, ESCs and hiPSCs
were plated on to VTN-coated plates containing Essential 8
(E8) xeno/feeder-free medium, at a density of 4–5 × 104 cells/
cm2. For coating, 5 μg/ml VTN (diluted in PBS; Thermo
Fisher Scientific, 14190–144) was applied to 60 mm diameter
tissue culture dishes for 1 h at room temperature. Culture
medium (E8) was changed daily until cells reached ~80%
confluency (usually 4 d after plating). The cells were then
passaged, frozen, or differentiated. A detailed protocol for
feeder-free hiPSC maintenance can be found in [80].
The optimized monolayer differentiation protocol for
human mDANs (see Figure 1A)
hiPSCs were cultured in E8 medium for up to 4 d, before
transferring to neural induction medium, comprising N2B27
medium supplemented with 100 nM LDN193189, 10 μM
SB431542, 200–500 ng/ml SHH and 0.6–1.0 μM CHIR (see
Results/Discussion); this was considered neuralization day 0.
Cells were passaged on PO/laminin-coated plates at neurali-
zation days 3 and 7 using Accutase, at a density of 4 × 104
cells/cm2 in neural induction medium supplemented with
10 μM Y27632 or 1:100 RevitaCell [80]. Media was changed
daily and was replaced with progenitor expansion medium
(N2B27 supplemented with 20 ng/ml BDNF, 20 ng/ml GDNF,
0.2 mM AA and 10 μM Y27632) on neuralization day 11.
When a full monolayer of cells was established, cells were
passaged on PO/laminin-coated plates in progenitor expan-
sion medium (cells can be expanded and passaged weekly in
this manner beyond day 50, with certain considerations [80]).
From day 16 onwards, terminal differentiation was initiated
by passaging and plating cells at a density of 5,000 cells/cm2 in
10–50 μl droplets on PO/laminin-coated coverslips in term-
inal differentiation medium, comprising N2B27 supplemented
with 20 ng/ml BDNF, 20 ng/ml GDNF, 0.2 mM ascorbic acid,
500 μM db-cAMP, 10 μM DAPT and 10 μM Y27632. Cells
were allowed to attach for ~1 h before coverslip-containing
wells were carefully flooded with the same media. Neurons
were fed at 3-d intervals by exchanging with ~50% N2B27
media supplemented with 20 ng/ml BDNF, 20 ng/ml GDNF,
0.2 mM ascorbic acid, 500 μM db-cAMP and 10 μM DAPT.
A detailed, stepwise differentiation protocol is available [80].
Light microscopy
Droplets of cells were plated on PO/laminin pre-coated cover-
slips in 4-well plates (Nunclon Delta Treated 4-Well IVF
Dish; Thermo Fisher Scientific, 144,444) or live imaging
dishes (35 mm glass-bottomed dishes; MatTek, P35 G-0.170-
14-C) and allowed to terminally differentiate for 7–14 d. For
fixed imaging, differentiated neurons were washed with PBS
(Sigma, D8537), then fixed in 4% paraformaldehyde for
20 min at room temperature, or in 100% −20°C methanol
for 5 min. After fixation, cells were washed twice with PBS
and permeabilized (paraformaldehyde-fixed cells only) using
0.2% Triton X-100 (Sigma, T9284), 5% normal donkey serum
(Sigma, S30-M), and 2% bovine serum albumin (Sigma,
A9647) in PBS for 1 h at room temperature. Cells were
incubated with primary antibody either overnight at 4°C, or
for 1 h at room temperature, according to the manufacturer’s
recommendations (see [80]). Following further PBS washes,
cells were incubated with fluorescent secondary antibodies in
the dark for 1 h at room temperature. Nuclei were stained
with 10 μg/ml Hoechst 33,342 or 100 ng/ml DAPI. Coverslips
were mounted on glass slides using Mowiol supplemented
with 25 mg/ml DABCO anti-fade. For live-cell imaging, cells
were plated on PO/laminin pre-coated and allowed to term-
inally differentiate for 10 d before imaging on the Olympus
IX-51 platform. In order to confirm the presence of DANs,
“on stage” immunolabeling was performed with stage posi-
tions recorded using MetaMorph. For mitochondrial and
lysosomal labeling, MT-GR, MT-R and LT-R dyes were
applied: before labeling, the cells were washed once with
PBS, followed by 30 min incubation (37°C/5% CO2) with
50 nM dyes in N2B27 supplemented with terminal differen-
tiation and maturation factors. Next, the cells were washed
twice with PBS, which was replaced with cell culture media.
For CYTO-ID staining, cells were incubated for 30 min in
N2B27 containing 2 μl/ml of CYTO-ID Green. Cells were
then washed and fixed with 4% paraformaldehyde and pro-
cessed for immunofluorescence imaging as above.
Wide-field microscopes used: Leica DMRD upright fluor-
escence microscope fitted with a Leica DFC450 C camera 5
Megapixel CCD sensor, with image capture and analysis per-
formed using a Leica Application Suite software; Olympus IX-
71 inverted microscope hosting a 60x Uplan Fluorite objective
(0.65–1.25 NA, oil) and fitted with a CoolSNAP HQ CCD
camera (Photometrics), with image capture and analysis per-
formed using MetaMorph software (Molecular Devices).
Confocal microscopy was performed using a Leica SP5-
AOBS laser-scanning confocal microscope (63x oil immersion
objective, 1.4 NA; or 100x oil immersion objective, 1.4 NA).
Electron microscopy
For electron microscopy, mDANs were seeded on 35 mm
glass-bottomed dishes as for light microscopy (above), and
treated with AZD8055 and/or BafA1 for 4 h. Cells were fixed
by the addition of 2% glutaraldehyde (EM grade) for 15 min
at room temperature. Following 3x washes with 0.1 M Na
Cacodylate buffer, cells were osmicated (1% OsO4 with 1.5%
K3[Fe{CN}6] in 0.1 M Na Cacodylate), washed, then dehy-
drated in an ethanol series before being embedded in Epon
resin. Hardened resin was removed from the imaging dish,
blocks were trimmed, and ~70 nm ultrathin sections cut using
an Ultracut S ultramicrotome (Leica). Sections were post-
stained in uranyl acetate and lead citrate and viewed using
a Technai 12 120 kV transmission electron microscope (FEI).
Images were obtained using a Ceta 4 k x 4 k CCD camera and
processed using Fuji software.
Lentiviruses
Lentiviruses were produced in HEK293 T as described [81]:
(i) PXLG3 GFP-LC3 (Lane lab); (ii) PRRL human SYN1-GFP
(gift from Prof. James Uney [University of Bristol]); (iii)
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PLVX EF1A GFP-ATG5 (Lane Lab). 45-50-d-old neural pro-
genitors were transduced with lentiviruses 2–4 d after plating.
After 3 d, media was replaced with fresh N2B27 media sup-
plemented with BDNF, GDNF, AA, db-cAMP and DAPT for
a further 3 d. Following a final media change, infected cells
were imaged live or used for flow cytometry.
Quantitative real-time polymerase chain reaction
(qRT-PCR)
Cells were plated in triplicate on 12-well plates at a density of
4x104/cm2. RNA was extracted by using the QIAGEN RNeasy
kit following the manufacturer’s instructions. Eluted RNA was
measured by a Nanodrop spectrophotometer (Thermo Fisher
Scientific). cDNA was prepared using a High Capacity RNA-to
-cDNA Kit (Thermo Fisher Scientific, 4,387,406) according to
the manufacturer’s instructions. cDNAs were amplified using
the SYBR Green Master Mix (Thermo Fisher Scientific,
4,309,155) and specific amplification primers (250 nM final
concentration) according to the manufacturer’s protocol,
using a StepOnePlus Real-Time PCR device (Applied
Biosystems). For 10 μl reactions, 2 μl of cDNA was mixed
with 2 μl of RNase-free H2O, 5 μl of SYBR Green, 0.5 μl
forward and 0.5 μl reverse primers. Cycle conditions set as
follows: an initial denaturation at 95°C for 10 min followed
40 cycles with 95°C for 15 s (denaturation), 60°C for 30 s
(annealing) and 60°C for 30 s (elongation). The relative quan-
tification of gene expression was performed via automatic
calculation of the cycle threshold (Ct) values for each target
gene and was normalized for the expression of the housekeep-
ing gene GAPDH (glyceraldehyde-3-phosphate dehydrogen-
ase), and was calculated using the 2(-ΔΔCt) method [82].












gaacca; OPTN: tgctgagtccgcacataga/gggtccatttcctgtgctt; SQST




50-55-d-old differentiated neuronal progenitors were plated in
12-well plates at a density of 6 × 104 cells/cm2 and allowed to
terminally differentiate for 10 d. 3 d after plating, cells were
transduced with PRRL human SYN1-GFP lentiviruses. 10
d post-plating, cells were treated for 3 h with DMSO (vehicle
control) or 10 μM CCCP and were then washed once with PBS
and probed with 50 nM MT-R for 30 min (37°C/5% CO2).
Following 2 washes with PBS, MT-R labeled cells were
dislodged into single cells by 10 min incubation in Accutase
(37°C/5%CO2), centrifuged (100 x g for 1 min) and resuspended
in fresh pre-warmed DMEM. Flow cytometry was performed
using a BD Influx cell sorter (BD Biosciences). Briefly, over
50,000 viable cells were recorded using the DRAQ7 DROP &
GO viability dye (Invitrogen, D15107). Cells were excited using
488 nm, 552 nm and 640 nm lasers, and fluorescence emissions
were captured for GFP (488 nm 530/40 nm BP), MT-R (552 nm
610/20 nm BP) and DRAQ7 (640 nm 750 LP) respectively. Data
were analyzed using FlowJo v10.3 software (Treestar).
Seahorse XFp bioanalyzer
To measure oxygen consumption rates (OCR) and extracel-
lular acidification rates (ECAR) in the presence of glucose or
galactose, an Agilent Seahorse XFp Analyzer (Santa Clara,
USA) with cell energy phenotype test kit was used (according
to the manufacturer’s instructions). 54-d-old neural progeni-
tors were plated on 8-well Seahorse XFp Cell culture mini-
plates (Agilent, 103022–100) at a density of 4 × 104 cells/cm2
and allowed to differentiate in N2B27 media supplemented
with BDNF, GDNF, AA, db-cAMP and DAPT. Depending on
the experimental conditions, 1 or 3 d prior to the assay, media
was replaced with Seahorse bioenergetics media consisting of
1:1 DMEM-F12 (no glucose) and Neurobasal (no glucose)
supplemented with 20 ng/ml BDNF, 20 ng/ml GDNF,
200 μM AA, 500 μM db-cAMP, 10 μM DAPT, 0.25 mM
sodium pyruvate and 10 mM galactose or 10 mM glucose
(instead of galactose). On the day of the assay, culture media
was replaced with Seahorse XF base medium supplemented
with 1 mM sodium pyruvate, 2 mM glutamine, and 10 mM
glucose or 10 mM galactose (depending on the condition; pH
7.4) and the cells were incubated at 37°C (without CO2) for
1 h before the assay. Data was extracted and analyzed auto-
matically by the Seahorse Wave software.
Statistical analysis
Mean differences were analyzed by student’s t-test, one-way
and two-way ANOVA (analysis of variance) followed by
Tukey’s (all values compared with each other) or Danette’s
(all values compared with a control value) multiple compar-
ison posthoc tests. Statistical significance was determined as
*p < 0.05, **p < 0.01 and ***p < 0.001 using GraphPad Prism
6 software (Graph Pad Software Inc., CA).
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